New hope in the treatment of
painful symptoms in depression

by
Briley M. NeuroBiz Consulting and Communications
Les Grezes La Verdarie 81100 Castres, France.
mike.briley@neurobiz.com
Curr Opin Investig Drugs. 2003 Jan;4(1):42-5


ABSTRACT

Depression is increasingly seen as a triad of psychological, somatic and physical symptoms that all need to be treated to achieve maximal remission. In primary care, physical symptoms such as pain, are the principal presenting symptoms, and a common psychopharmacology between pain and depression suggests that compounds that inhibit the reuptake of both serotonin and norepinephrine are likely to produce the greatest relief from depression and chronic pain. Recent, principally open, trials with members of the new selective serotonin and norepinephrine reuptake inhibitor class of antidepressants such as venlafaxine, milnacipran and duloxetine (Eli Lilly & Co/Shionogi & Co Ltd), suggest that these compounds may be effective in relieving pain both associated with, and independent of depression.
SNRIs
Serotonin
Dopamine
Milnacipran
Venlafaxine
Noradrenaline
Duloxetine 2002
Alpha2 antagonism
The Drug Companies
Duloxetine: hope or hype?
Duloxetine and depression
Duloxetine for fibromyalgia
Duloxetine-induced nausea
Duloxetine for major depression
Duloxetine (Cymbalta): structure
Duloxetine for anxious depressives
Duloxetine (Cymbalta), serotonin and noradrenaline
Duloxetine (Cymbalta) and painful physical symptoms
Duloxetine, a balanced serotonin-noradrenaline reuptake inhibitor


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family